About

Andrew Booth has served as AbCellera's Chief Financial Officer since August 2019 and previously served on the company's Board of Directors from June 2016 to August 2019, playing a key role in the company's 2020 Nasdaq IPO. Before AbCellera he spent roughly a decade at Vancouver-based STEMCELL Technologies Inc., serving as Chief Commercial Officer (2017-2019), Chief Financial Officer (2013-2017) and VP, Instrumentation (2010-2013). Earlier he spent seven years at GE, concluding as leader of M&A for GE Healthcare's EMEA and global Life Sciences businesses in London. He holds an MBA from INSEAD and a B.A.Sc. in Engineering Physics from the University of British Columbia.

Roles

AbCellera Biologics Inc.
Chief Financial Officer · Current role
August 2019–present
AbCellera Biologics Inc.
Member of the Board of Directors
June 2016 - August 2019
STEMCELL Technologies Inc.
Chief Commercial Officer
February 2017 - July 2019
STEMCELL Technologies Inc.
Chief Financial Officer
March 2013 - January 2017
GE Healthcare
M&A leader, EMEA and Life Sciences · Based in London, UK
2004 - 2009

External Roles

Aspect Biosystems
Director
Karius Diagnostics
Director
5AM Venture Capital
Advisor

Fixed Compensation

FY 2025
Salary
$485,000
ComponentAnnual base salary earned in FY2025 (USD)
All other compensation
$23,244
ComponentRRSP employer contributions
Total compensation
$3,382,244

Performance Compensation

Data from FY 2025

Cash incentive

Bonus
$218,567
Target Opportunity
PlanDiscretionary annual cash incentive bonus for 2025 (45% of base-salary target)

Stock awards

Stock options
$2,655,434
FormStock options, ASC 718 grant-date fair value (NEO long-term incentives are 100% options)

Also at AbCellera Biologics Inc.

Related

See how VectorShift works for your firm

Request Demo